A Martin Shkreli wannabe defends a big spike in drug price and earns a Twitter lashing from the FDA's commish

There’s a broad consensus that the pharma industry has at least temporarily checked its impulse to keep hiking prices on their portfolios. But a small drugmaker named Nostrum Laboratories appears not to have received the memo — and now the company is on the receiving end of a Twitter-lashing by FDA commissioner Scott Gottlieb.